Table 2.
Comorbidities, living environment, and gender distributions among IPs.
| Comorbidity | Living environment | Gender | Total, n (%) | ||
|---|---|---|---|---|---|
| Rural, n (%) | Urban, n (%) | F, n (%) | M, n (%) | ||
| Cancer history | 16 (42.11%) | 22 (57.89%) | 25 (65.79%) | 13 (34.21%) | 38 (26.57%) |
| Immunosuppressants | 6 (50.00%) | 6 (50.00%) | 12 (100%) | — | 12 (8.39%) |
| DM | 37 (54.41%) | 31 (45.59%) | 32 (47.06%) | 36 (52.94%) | 68 (47.55%) |
| CKD | 9 (75.00%) | 3 (25.00%) | 4 (33.33%) | 8 (66.67%) | 12 (8.39%) |
| Chronic infections | 5 (38.46%) | 8 (61.54%) | 2 (15.38%) | 11 (84.62%) | 13 (9.09%) |
| p = 0.2799a | p < 0.001a | p < 0.001b | |||
CKD, chronic kidney disease; DM, diabetes mellitus.
a
Fisher exact test.
b
Chi-square-goodness-fit.